Malaria Vaccine Antibody Avidity and Function Analysis

Supplementary data from two clinical trials investigating Plasmodium falciparum vaccines. The document contains results on antibody avidity, Fc-mediated functional activities, and longevity from a phase 1 trial in malaria-naïve adults and a phase 2b trial in African children. Authored by Jessica L Horton and published on figshare in April 2026.

Use Cases

• Analyze the relationship between IgG magnitude and antibody avidity across different vaccine antigens and adjuvants.
• Model the association between antibody avidity and Fc-mediated functional activities like complement fixation and opsonic phagocytosis.
• Assess the correlation between antibody avidity and antibody longevity for specific antigens like merozoite surface protein 2 and RTS,S.
• Compare immunological outcomes from trials in distinct populations: malaria-naïve adults versus African children.

Strengths

• Data derived from two distinct clinical trial phases (phase 1 and phase 2b) for cross-validation.
• Analysis includes multiple functional activity metrics: complement fixation, Fcγ-receptor binding, and opsonic phagocytosis.

Limitations

• The dataset is a 340.3 KB DOCX file, limiting direct computational analysis and requiring manual extraction.
• No raw columnar data or sample records are provided, only summarized results in a document format.
• Specific sample sizes, row counts, and granular patient-level data are not available.

Provenance

Source

figshare, authored by Jessica L Horton.

Collection Method

Analysis of immunological data from two Plasmodium falciparum vaccine clinical trials.

Time Range

Temporal coverage of the underlying clinical trials is not specified.

Freshness

Last updated April 2026.

Geography

Trials conducted with malaria-naïve adults (location unspecified) and African children.